AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Phase I, Open-Label, Dose-Escalation Study of AZD4877 in Solid Tumors
Phase 1
Completed
- Conditions
- Neoplasms
- First Posted Date
- 2006-10-18
- Last Posted Date
- 2009-05-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 75
- Registration Number
- NCT00389389
- Locations
- 🇺🇸
Research Site, Houston, Texas, United States
Efficacy and Safety Study of Seroquel SR in the Treatment of Major Depressive Disorder
Phase 3
Completed
- Conditions
- Major Depressive Disorder
- First Posted Date
- 2006-10-17
- Last Posted Date
- 2010-04-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 338
- Registration Number
- NCT00388973
- Locations
- 🇺🇦
Research Site, Vinnitsa, Ukraine
Symbicort Single Inhaler Therapy vs Conventional Best Practice for the Treatment of Persistent Asthma in Adults
Phase 3
Terminated
- Conditions
- Asthma, Bronchial
- First Posted Date
- 2006-10-09
- Last Posted Date
- 2010-12-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 654
- Registration Number
- NCT00385593
- Locations
- 🇪🇸
Research Site, Zaragoza, Spain
The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST).
Phase 2
Completed
- Conditions
- Gastrointestinal Stromal TumorsSoft Tissue Sarcomas
- First Posted Date
- 2006-10-06
- Last Posted Date
- 2012-07-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 35
- Registration Number
- NCT00385203
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
A Study of Ciclesonide Nasal Spray in Patients 18 Years and Older With Seasonal Allergic Rhinitis (BY9010/M1-413)
Phase 3
Completed
- Conditions
- Rhinitis, Allergic, SeasonalHay Fever
- First Posted Date
- 2006-10-06
- Last Posted Date
- 2016-11-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 500
- Registration Number
- NCT00384475
- Locations
- 🇨🇦
Altana Pharma/Nycomed, Ontario, Mississauga, Canada
PPI Sequencing Study
Phase 4
Completed
- Conditions
- Gastro-Oesophageal Reflux Disease
- First Posted Date
- 2006-10-06
- Last Posted Date
- 2009-03-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100
- Registration Number
- NCT00384592
- Locations
- 🇬🇧
Research Site, Warminster, United Kingdom
🇬🇧Research SIte, Glasgow, United Kingdom
A Comparative Study of Inhaled Ciclesonide Versus Placebo in Children (6-11 Years) With Asthma
- First Posted Date
- 2006-10-05
- Last Posted Date
- 2017-02-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1080
- Registration Number
- NCT00384189
- Locations
- 🇺🇦
Altana Pharma/Nycomed, Zaporizhzhya, Ukraine
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
Phase 2
Completed
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2006-10-05
- Last Posted Date
- 2017-04-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1814
- Registration Number
- NCT00384176
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Antihypertensive Efficacy and Safety of Candesartan/HCT 32/12.5 and 32/25 mg in Comparison With Candesartan 32 mg
Phase 3
Completed
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2006-10-04
- Last Posted Date
- 2008-03-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1979
- Registration Number
- NCT00383929
- Locations
- 🇩🇪
Research SIte, Hann, Germany
🇬🇧Research Site, Wokingham, United Kingdom
A Study to Assess the Effect on Glucose Control and Safety and Tolerability of LY2148568 In Japanese Patients With Type 2 Diabetes
Phase 2
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: PlaceboDrug: exenatide (LY2148568)
- First Posted Date
- 2006-09-28
- Last Posted Date
- 2015-02-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 153
- Registration Number
- NCT00382239
- Locations
- 🇯🇵
Research Site, Tokyo, Japan
© Copyright 2025. All Rights Reserved by MedPath